Interfering with Interferon

Moderator(s)

• 

  Michael Ombrello, MD

  Pediatric Rheumatologist
  National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)

Speaker(s)

• RG

  Raphaela Goldbach-Mansky, MD

  NIH/NIAID
• 

  Hanna Kim, MD, MS

  National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)

Genetically-mediated mendelian interferonopathies are associated with very high interferon-regulated gene expression, and may result in severe autoinflammatory diseases. Janus kinase inhibitors have demonstrated efficacy in the treatment of mendelian interferonopathies. Insights from recent discoveries regarding the treatment of mendelian interferonopathies may provide additional treatment options for the treatment of juvenile dermatomyositis (JDM). This talk highlights the bench-to-bedside research involving complex rheumatic diseases, including the mendelian interferonopathies, and explains potential applications to other rheumatic diseases, including JDM.

Learning Objectives:

• Describe key features and genetic causes of mendelian interferonopathies
• Describe treatment strategies for mendelian interferonopathies
• Review the role of type-I interferon in broader autoimmune diseases with an interferon signature (i.e., JDM) and what can be learned or translated from mendelian interferonopathies

Presentations:

• 12:00 PM – 12:20 PM ET

  The Expanding Spectrum of Mendelian Interferonopathies Unravel Underpinnings of Type I IFN Signaling
  Raphaela Goldbach-Mansky, MD – NIH/NIAID
• 12:20 PM – 12:40 PM ET

  Interferon in Juvenile Dermatomyositis (JDM) – What can we learn from Mendelian Interferonopathies
  Hanna Kim, MD, MS – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
• 12:40 PM – 1:00 PM ET

  Q&A